Search research articles
Contact Us
Filters
Showing results (11-20 of 120) with videos related to
Page
of 12
Sort By:
Addiction Biology
|
September 11, 2008
Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats
Miriam Schneider, Edgar Schömig, F Markus Leweke
Pharmacopsychiatry
|
January 24, 2024
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits - A Critical Review
Inga Dammann, Cathrin Rohleder, F Markus Leweke
Expert Opinion on Pharmacotherapy
|
April 14, 2015
Drug repurposing and emerging adjunctive treatments for schizophrenia
Jan Malte Bumb, Frank Enning, F Markus Leweke
CNS Drugs
|
November 4, 2004
Cannabis-associated psychosis: current status of research
F Markus Leweke, Christoph W Gerth, Joachim Klosterkötter
Current Opinion in Psychiatry
|
February 20, 2020
Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies
Julie Schoevers, Judith E Leweke, F Markus Leweke
Future Medicinal Chemistry
|
October 15, 2016
What is the promise of nicotinergic compounds in schizophrenia treatment?
Juliane K Mueller, Cathrin Rohleder, F Markus Leweke
Handbook of Experimental Pharmacology
|
November 7, 2012
Medical needs in the treatment of psychotic disorders
F Markus Leweke, Thorsten M Odorfer, J Malte Bumb
BMC Bioinformatics
|
October 16, 2009
Clinical bioinformatics for complex disorders: a schizophrenia case study
Emanuel Schwarz, F Markus Leweke, Sabine Bahn, et al.
Frontiers in Psychiatry
|
March 20, 2023
Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state
Dagmar Koethe, Cathrin Rohleder, Lutz Kracht, et al.
Biological Psychiatry
|
February 8, 2016
Therapeutic Potential of Cannabinoids in Psychosis
F Markus Leweke, Juliane K Mueller, Bettina Lange, et al.
Page
of 12
Search research articles
Search
Showing results (11-20 of 120) with videos related to
Sort By:
Page
of 12
Addiction Biology
|
September 11, 2008
Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats
Miriam Schneider, Edgar Schömig, F Markus Leweke
Pharmacopsychiatry
|
January 24, 2024
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits - A Critical Review
Inga Dammann, Cathrin Rohleder, F Markus Leweke
Expert Opinion on Pharmacotherapy
|
April 14, 2015
Drug repurposing and emerging adjunctive treatments for schizophrenia
Jan Malte Bumb, Frank Enning, F Markus Leweke
CNS Drugs
|
November 4, 2004
Cannabis-associated psychosis: current status of research
F Markus Leweke, Christoph W Gerth, Joachim Klosterkötter
Current Opinion in Psychiatry
|
February 20, 2020
Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies
Julie Schoevers, Judith E Leweke, F Markus Leweke
Future Medicinal Chemistry
|
October 15, 2016
What is the promise of nicotinergic compounds in schizophrenia treatment?
Juliane K Mueller, Cathrin Rohleder, F Markus Leweke
Handbook of Experimental Pharmacology
|
November 7, 2012
Medical needs in the treatment of psychotic disorders
F Markus Leweke, Thorsten M Odorfer, J Malte Bumb
BMC Bioinformatics
|
October 16, 2009
Clinical bioinformatics for complex disorders: a schizophrenia case study
Emanuel Schwarz, F Markus Leweke, Sabine Bahn, et al.
Frontiers in Psychiatry
|
March 20, 2023
Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state
Dagmar Koethe, Cathrin Rohleder, Lutz Kracht, et al.
Biological Psychiatry
|
February 8, 2016
Therapeutic Potential of Cannabinoids in Psychosis
F Markus Leweke, Juliane K Mueller, Bettina Lange, et al.
Page
of 12